Focus Rheums| Dr. Jekyll or Mr. Hyde? (video)

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: cardiovascular risk

A Medical Research Career Fueled by Curiosity

  |  

In January, Cecilia Pilar Chung, MD, MPH, began her new appointment as director of the Division of Rheumatology at the University of Miami. Previously, Dr. Chung was an associate professor of medicine at Vanderbilt University, Nashville, Tenn., for more than 10 years. At Vanderbilt, Dr. Chung built a strong research portfolio, focusing on the comparative…

Highlights from the ACR Review Course 2022

  |  

PHILADELPHIA—At ACR Convergence 2022, the much-anticipated ACR Review Course featured talks from eight experts. Topics reflected the heterogeneity of our field and included Sjögren’s disease, spondyloarthritis (SpA), osteoarthritis (OA), paraneoplastic rheumatic syndromes, metabolic bone disease, statin myopathy, Raynaud’s phenomenon and autoinflammatory syndrome. Here, I share highlights from this comprehensive, six-hour session. Sjögren’s Disease Sara S….

String of Pearls: Lessons in Rheumatoid Arthritis

  |  

PHILADELPHIA—William “Bill” R. Palmer, MD, MACR, was the first board-certified rheumatologist in Omaha, Neb., where he spent his entire 43-year clinical career and established himself as a great clinician, mentor and educator. Although Dr. Palmer passed away from metastatic thyroid cancer in August 2021, his memory lives on through his physician colleagues and at ACR…

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

Walter P. Maksymowych, MB ChB, FACP, FRCP(C)  |  

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

Psoriatic Arthritis & the Obese Patient

Linda Kossoff  |  

Estimates from the National Psoriasis Foundation indicate that more than 8 million people in the U.S. suffer from psoriasis and that approximately 30% of those individuals develop psoriatic arthritis (PsA).1 Given these statistics, roughly 2.4 million people in the country are likely affected by PsA. Moreover, patients with this systemic condition carry a higher-than-average burden…

Vasculitis Guidelines in Focus, Part 6: Giant Cell Arteritis

Michael Putman, MD  |  

In 2021, the ACR—in concert with the Vasculitis Foundation (VF)—released four new vasculitis guidelines, one each on: 1) anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, 2) giant cell arteritis (GCA) and Takayasu arteritis, 3) polyarteritis nodosa and 4) Kawasaki disease. The guideline development process is complex. For the vasculitis guidelines, this process kicked off in June…

A Young Disease: A Holistic Approach to the Treatment of Antiphospholipid Syndrome

  |  

Although progress has been made in recent years, rheumatologists still have a lot of questions regarding best management practices for antiphospholipid syndrome (APS). During a session of EULAR 2022, Ricard Cervera, MD, PhD, described a holistic approach.

A Guiding Light for RA: Insights into Clinical Decision Making, Drug Safety & More

  |  

The treatment and management of rheumatoid arthritis (RA) is ever evolving. Here Clifton O. Bingham, MD, discusses the application of RA guidelines, the most recent drug safety information and more.